Ultrasound-Enhancing Agents Market is expected to reach US$ 2,511.52 million by 2031

Market for Abdominal Imaging Segment to Grow Considerably During 2023–2031

According to our new research study on "Ultrasound-Enhancing Agents Market Forecast (2021–2031), Global Share, Trend, and Growth Opportunity Analysis – by Type, Application, End User, and Geography," the market was valued at US$ 756.61 million in 2023 and is projected to reach US$ 2,511.52 million by 2031; it is estimated to record a CAGR of 16.2% during 2023–2031. The rising adoption of ultrasound-enhancing agents in diagnostic imaging and the increasing regulatory support and product approvals drive the market growth. However, the dearth of skilled technicians and the high cost of diagnostic procedures hinder the ultrasound-enhancing agents market growth.

Ultrasound-Enhancing Agents Market Trends:

Rising focus on the development of improved formulations with enhanced stability, longer circulation times, and targeted binding properties is likely to add novel products to the market. Recent advancements in contrast agents have revolutionized the field of cellular and molecular imaging, enhancing the accuracy of early-stage disease detection. The use of nanoparticles with suitable structures and superior binding capabilities facilitates targeted imaging and disease detection. Such ultrasound-enhancing agents can be built by designing acoustically sensitive agents for disease-specific imaging, developing signal processing techniques to obtain high-resolution vascular images, and creating interpretation techniques to extract biologically and physiologically relevant data from microbubble acoustic signatures. The emergence of new ultrafast imaging and image processing techniques, coupled with the growing interest in targeted ultrasound therapeutic applications, are likely to support the use of ultrasound in numerous unexplored applications. The signal of agents depends on their size, and currently, the market is dominated by large-sized agents. This limits their use in molecular imaging, including cancer detection. However, smaller agents (100–500 nm) are being developed using nanomedicine. These agents can utilize tumor permeability and expand the capabilities of ultrasound in targeted cancer detection and therapy.

Ultrasound Enhancing Agents Market, by Geography, 2023 (%)

Source: The Insight Partners Analysis

Further, improvements in pediatric ultrasound imaging techniques, including ultrasound-enhancing agents, are anticipated to cater to the specific needs of pediatric patients. The introduction of child-friendly contrast-enhancing agents, dose-optimization strategies, and personalized imaging protocols may address the unique challenges associated with imaging in pediatrics, in turn ensuring the safety and efficacy of diagnostics.

Segmental Analysis:

The “ultrasound-enhancing agents market analysis” has been performed by considering the following segments: type, application, and end user.

By type, the market is bifurcated into first generation and second generation. The second-generation segment held a larger market share in 2023. It is projected to register a higher CAGR from 2023 to 2031. Second-generation ultrasound-enhancing agents are made with microbubbles of inert and slowly diffusing gases, such as sulfur hexafluoride, or perfluorobutane stabilized in a phospholipid membrane. SonoVue, Definity, Optison, and Sonazoid are a few of the second-generation ultrasound-enhancing agents available in the market. The rising adoption of these products for better visualization of tumors and abnormal tissue growth propels the ultrasound-enhancing agents market growth.

The market, by application, is segmented into abdominal imaging, cardiovascular imaging, urinary tract imaging, and others. The abdominal imaging segment held the largest ultrasound-enhancing agents market share in 2023. The cardiovascular imaging segment is projected to register the highest CAGR from 2023 to 2031.

The market, by end user, is segmented into hospitals, diagnostic and imaging centers, and others. The hospitals segment held the largest share of the market in 2023. According to an article published by ScienceDirect in April 2020, the contrast-enhanced ultrasound (CEUS) method is becoming more popular in hospital settings due to its effectiveness in enabling a noninvasive, real-time evaluation of blood flow to aid in lesion characterization. It is considered a safer alternative to MRI or CT as it does not involve exposing subjects to ionizing radiation. This has made it a preferred choice for patients who require frequent imaging. As a result, the demand for CEUS in hospitals has been increasing, leading to its wider use. Further, the diagnostic and imaging centers segment is expected to register the highest CAGR from 2023 to 2031.

The scope of the ultrasound-enhancing agents market report entails North America (US, Canada, and Mexico), Europe (Spain, UK, Germany, France, Italy, and Rest of Europe), Asia Pacific (South Korea, China, India, Japan, Australia, and Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, UAE, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America). Asia Pacific is expected to register the fastest CAGR in the market from 2023 to 2031. Market growth in this region is attributed to the preference for advanced research tools in ongoing clinical studies, as well as increasing healthcare expenditures in the region. In terms of revenue, North America accounted for the largest ultrasound-enhancing agents market share in 2023.

A few initiatives taken by key players operating in the ultrasound-enhancing agents market are listed below:

• In March 2024, Lantheus Holdings, Inc. announced the approval of the US Food and Drug Administration (FDA) for its supplemental new drug application (sNDA) for DEFINITY for its use as an ultrasound-enhancing agent in pediatric patients producing suboptimal echocardiograms.
• In April 2022, PerkinElmer announced the expansion of its in vivo imaging portfolio with the launch of the Vega imaging system. It is a hands-free, automated, high-throughput preclinical ultrasound imaging system that delivers high-resolution 2D and 3D ultrasound images. The system is complemented by VesselVue microbubble contrast agents, which can be used to study tissue perfusion and blood flow characteristics.

Competitive Landscape

Lantheus Holdings Inc.; GE Healthcare; Solstice Pharmaceuticals BV; FUJIFILM VisualSonics, Inc.; Bracco Diagnostics Inc.; Bayer AG; and Vesselon are among the leading companies profiled in the ultrasound-enhancing agents market report. The companies implement both organic (such as product launches, expansion, and product approvals) and inorganic (such as collaborations and partnerships) strategies to stay competitive in the market.

Contact Us
 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com